BMI has developed proprietary technology that overcomes immunological, technical, and safety issues associated with the current vaccines, while also enabling a more rapid and lower cost manufacturing process.
ultraIPV is produced using proprietary inactivation technology. Viruses are complexed with a manganese-decapeptide-phosphate (MDP) mixture and then exposed to UV light. A very quick, easy and reproducible process. The MDP system has been adapted from radiation-resistant bacteria such as Deinococcus radiodurans.
The use of attenuated Sabin strains to produce the vaccine greatly reduces safety and biosecurity concerns. This non-chemical inactivation process uses ultraviolet light resulting in reduced damage to the immunogenic surface features of the virus.
BMI's process is rapid (less than a minute compared with 2-4 weeks for formalin-inactivation) and requires less downstream processing than IPV.
ultraIPV vaccine stimulates high titers of virus-neutralizing antibodies in animal models.
Mass spectrometric analysis of ultraIPV and two commercially available IPV products indicate that many more doses of ultraIPV can be made than IPV per starting quantity of virus.
ultraIPV is expected to have a similar safety profile as IPV in vaccines with the exception that the use of formaldehyde is avoided.
The animations below illustrate:
Chain 1 - VP1 - green; Chain 2 - VP2 - blue
Chain 3 - VP3 - red/pink; Chain 5 - VP3 - orange
Chain 6 - VP3 - white; Chain 7 - VP2 - white
Chain 8 - VP1 - orange